Video

What are the clinical best practices and how can the VA expand these specialty care innovations and patient care advances across the entire health care system? To understand the progress being made by the VA, Federal Practitioner sat down with Assistant Deputy Under Secretary for Health, for Quality, Safety, and Value Shereef M. Elnahal, MD, MBA, at the Launch Pad: Pathways to Cancer Innovation summit to discuss the Diffusion of Excellence program he is currently leading.  

Dr. Elnahal discusses the development of virtual tumor, clinical pharmacy specialists, and the more than 400 other programs under consideration as well as the many programs already being replicated across multiple sites.

What are the clinical best practices and how can the VA expand these specialty care innovations and patient care advances across the entire health care system? To understand the progress being made by the VA, Federal Practitioner sat down with Assistant Deputy Under Secretary for Health, for Quality, Safety, and Value Shereef M. Elnahal, MD, MBA, at the Launch Pad: Pathways to Cancer Innovation summit to discuss the Diffusion of Excellence program he is currently leading.  

Dr. Elnahal discusses the development of virtual tumor, clinical pharmacy specialists, and the more than 400 other programs under consideration as well as the many programs already being replicated across multiple sites.

What are the clinical best practices and how can the VA expand these specialty care innovations and patient care advances across the entire health care system? To understand the progress being made by the VA, Federal Practitioner sat down with Assistant Deputy Under Secretary for Health, for Quality, Safety, and Value Shereef M. Elnahal, MD, MBA, at the Launch Pad: Pathways to Cancer Innovation summit to discuss the Diffusion of Excellence program he is currently leading.  

Dr. Elnahal discusses the development of virtual tumor, clinical pharmacy specialists, and the more than 400 other programs under consideration as well as the many programs already being replicated across multiple sites.

SAN ANTONIO – Every day, practicing oncologists sort through mountains of data from treatment guidelines, clinical trials, protocols, and algorithms to make the best possible therapeutic decisions for their patients.

At Manipal Hospitals in Bangalore, India, those decisions are informed with the aid of Watson for Oncology (WFO), a software platform developed by IBM in concert with clinicians and investigators at Memorial Sloan Kettering Cancer Center in New York City.

In this video interview at the San Antonio Breast Cancer Symposium, S.P. Somashekhar, MBBS, MS, MCH, chairman of the Manipal Comprehensive Cancer Center, discusses how the system is used by the members of the center’s multidisciplinary tumor board to inform decision making. He also describes results of a study he presented at the symposium that shows a relatively high degree of concordance between clinician and WFO choices in the treatment of patients with local breast cancer but less agreement when it comes to the management of metastatic disease, for which there is no universal standard of care.

SAN ANTONIO – Every day, practicing oncologists sort through mountains of data from treatment guidelines, clinical trials, protocols, and algorithms to make the best possible therapeutic decisions for their patients.

At Manipal Hospitals in Bangalore, India, those decisions are informed with the aid of Watson for Oncology (WFO), a software platform developed by IBM in concert with clinicians and investigators at Memorial Sloan Kettering Cancer Center in New York City.

In this video interview at the San Antonio Breast Cancer Symposium, S.P. Somashekhar, MBBS, MS, MCH, chairman of the Manipal Comprehensive Cancer Center, discusses how the system is used by the members of the center’s multidisciplinary tumor board to inform decision making. He also describes results of a study he presented at the symposium that shows a relatively high degree of concordance between clinician and WFO choices in the treatment of patients with local breast cancer but less agreement when it comes to the management of metastatic disease, for which there is no universal standard of care.

SAN ANTONIO – Every day, practicing oncologists sort through mountains of data from treatment guidelines, clinical trials, protocols, and algorithms to make the best possible therapeutic decisions for their patients.

At Manipal Hospitals in Bangalore, India, those decisions are informed with the aid of Watson for Oncology (WFO), a software platform developed by IBM in concert with clinicians and investigators at Memorial Sloan Kettering Cancer Center in New York City.

In this video interview at the San Antonio Breast Cancer Symposium, S.P. Somashekhar, MBBS, MS, MCH, chairman of the Manipal Comprehensive Cancer Center, discusses how the system is used by the members of the center’s multidisciplinary tumor board to inform decision making. He also describes results of a study he presented at the symposium that shows a relatively high degree of concordance between clinician and WFO choices in the treatment of patients with local breast cancer but less agreement when it comes to the management of metastatic disease, for which there is no universal standard of care.